Carsten S.
- Country
- Germany
- Department
- Onkologisch-Hämatologische Schwerpunktpraxis
Research Overview
- Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/bortezomib/dexamethasone (I-VRD) followed by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followed by one cycle of high-dose therapy and maintenance therapy with lenalidomide and isatuximab
- Venetoclax in combination with the BTK inhibitor Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with treatment naive Mantle Cell Lymphoma not eligible for high dose therapy
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 58 of 250 partner sites.
Specializations
Early Breast Cancer Research
This investigator specializes in advanced therapeutic approaches for early-stage breast cancer, with particular focus on triple-negative and HR+/HER2- subtypes.
- Triple-negative breast cancer treatment optimization
- Hormone receptor-positive therapy innovation
- Neoadjuvant treatment strategies
The research encompasses novel combinations of immunotherapy and targeted treatments for early-stage breast cancer management.
Advanced Breast Cancer Studies
The investigator conducts research in metastatic breast cancer treatment, focusing on hormone receptor-positive HER2-negative disease variants.
- Endocrine therapy combinations
- Progressive disease management
- Digital side effect monitoring
Their work includes evaluation of targeted therapies and survival outcomes in advanced breast cancer settings.
Lymphoma Treatment
The investigator's expertise extends to advanced Hodgkin Lymphoma treatment optimization.
- Treatment-related morbidity reduction
- Progressive therapy protocols
- Radiotherapy integration
Research focuses on developing less toxic treatment regimens while maintaining therapeutic efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.